Inhibrx Announces Participation in Upcoming Scientific Conferences

Rhea-AI Summary

Inhibrx (Nasdaq: INBX) announced presentations and a poster at three upcoming scientific conferences in November 2025 covering clinical and preclinical data for the DR5 agonist ozekibart (INBRX-109) and related DR5 clinical results.

Events and highlights:

• Nov 5, 2025 — La Jolla: DR5 agonist clinical data presentation by Josep Garcia, PhD and Katelyn Willis, PhD.
• Nov 14, 2025 — Boca Raton (CTOS): Phase 2 ChonDRAgon randomized registrational results in conventional chondrosarcoma (lead author Robin L. Jones, MD).
• Nov 22, 2025 — Honolulu (SNO): Poster on INBRX-109 anti-tumor activity in GBM models, monotherapy and with TMZ.

Presentations and the poster will be accessible via the company investor events page when each event begins.

News Market Reaction

+0.68%

1 alert

+0.68% News Effect

On the day this news was published, INBX gained 0.68%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

SAN DIEGO, Nov. 4, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, today announced it will be presenting at the following upcoming scientific conferences:

21^st Annual Industry/Academia Precision Oncology & Radmed Symposium
November 5^th, 2025 – La Jolla, California

Title:  DR5 Agonist Clinical Data in Chondrosarcoma, Colorectal Cancer and Ewings Sarcoma
Format: Presentation
Presenters: Josep Garcia, PhD, Executive Vice President, Chief Clinical Development Officer, Inhibrx; Katelyn Willis, PhD, Director, Biotherapeutics, Inhibrx
Date: Wednesday, November 5^th, 2025
Time: 4:45 PM Eastern Standard Time
Location:   The Alexandria at Torrey Pines, La Jolla, California

Connective Tissue Oncology Society (CTOS) 2025 Annual Meeting
November 12^th – 15^th, 2025 – Boca Raton, Florida

Title: The Tetravalent Death Receptor 5 (DR5) Agonist ozekibart (INBRX-109) in Conventional Chondrosarcoma: Results from the Randomized, Registrational, Phase 2 ChonDRAgon Study
Lead Author: Robin L. Jones, MD – Medical Oncology, The Royal Marsden and Institute of Cancer Research
Format: Presentation
Date: Friday, November 14^th, 2025
Time: 8:30 AM – 10:00 AM Eastern Standard Time
Location: The Boca Raton, Boca Raton, Florida

Society for NeuroOncology (SNO) 2025 Annual Meeting
November 19^th – 23^rd, 2025 – Honolulu, Hawaii

Title: The Tetravalent Death Receptor 5 (DR5) agonist ozekibart (INBRX-109) exhibits anti-tumor activity in GBM models as a monotherapy and in combination with TMZ
Format: Poster Presentation
Date: Saturday, November 22^nd, 2025
Time: 4:45 pm – 6:00 PM Eastern Standard Time
Location: Hawaii Convention Center, Honolulu, Hawaii; Kamehameha Exhibit Hall II & III

The presentation and poster will be accessible through a link on the investors' section of Inhibrx's website at https://inhibrxbiosciences.investorroom.com/events-and-presentations upon commencement of each event.

About Inhibrx Biosciences, Inc.

Inhibrx Biosciences is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates. Inhibrx Biosciences utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. Inhibrx Biosciences was incorporated in January 2024 as a direct, wholly-owned subsidiary of Inhibrx, Inc. Prior to the sale of Inhibrx, Inc. and the INBRX-101 program to Sanofi S.A., Inhibrx Biosciences acquired certain corporate infrastructure and other assets and liabilities through a series of internal restructuring transactions effected by Inhibrx, Inc. Inhibrx, Inc. also completed a distribution to holders of its shares of common stock of 92% of the issued and outstanding shares of Inhibrx Biosciences. Following such transactions, Inhibrx Biosciences' current clinical pipeline of therapeutic candidates includes ozekibart and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what we believe to be the most appropriate agonist function. For more information, please visit www.inhibrx.com.

Investor and Media Contact:

Kelly Deck, CFO
ir@inhibrx.com
858-795-4260

View original content to download multimedia:https://www.prnewswire.com/news-releases/inhibrx-announces-participation-in-upcoming-scientific-conferences-302604643.html

SOURCE Inhibrx Biosciences, Inc.

FAQ

When will Inhibrx (INBX) present DR5 clinical data in La Jolla?

Inhibrx will present on Nov 5, 2025 at 4:45 PM ET at the Precision Oncology & Radmed Symposium in La Jolla.

What will Inhibrx present at CTOS 2025 for INBX-109 (ozekibart)?

A presentation of the randomized, registrational Phase 2 ChonDRAgon study results in conventional chondrosarcoma on Nov 14, 2025 at 8:30 AM ET.

Where and when is the INBRX-109 GBM poster presentation for Inhibrx (INBX)?

A poster on anti-tumor activity in GBM models will be presented on Nov 22, 2025 at 4:45 PM ET at SNO 2025 in Honolulu.

Who are the Inhibrx presenters for the Nov 5, 2025 La Jolla presentation?

Presenters are Josep Garcia, PhD, EVP & Chief Clinical Development Officer, and Katelyn Willis, PhD, Director, Biotherapeutics.

Will Inhibrx make the presentations available online for investors?

Yes. Each presentation and the poster will be accessible via a link on the Inhibrx investor events page upon commencement of each event.

Which DR5 program will Inhibrx (INBX) discuss across the November 2025 meetings?

Inhibrx will discuss the DR5 agonist ozekibart (INBRX-109) and clinical/preclinical data across the listed meetings.